Use of a promoter of T-cell expansion and an inducer of CD40...

Details Use of a promoter of T-cell expansion and an inducer of CD40... Use of a promoter of T-cell expansion and an inducer of CD40...

2008-05-06

2008-05-06

Mertz, Prema (Department: 1646)

Drug, bio-affecting and body treating compositions

Lymphokine

Interleukin

C424S141100, C424S143100, C424S130100, C514S002600, C514S008100, C514S012200

Reexamination Certificate

active

07368106

ABSTRACT:
The invention provides a method of treating or preventing a pathologic state in a mammal. The method comprises administering to the mammal a promoter of T-cell expansion and an inducer of CD40 stimulation, wherein CD40 is stimulated on cells of the immune system. The promoter of T-cell expansion and inducer of CD40 stimulation are administered in synergistically effective amounts to treat or prevent the pathologic state in the mammal. The invention also provides a method of assessing the effectiveness of treatment of a pathologic state in a mammal, wherein the mammal has been administered a promoter of T-cell expansion and an inducer of CD40 stimulation, wherein CD40 is stimulated on cells of the immune system. The method comprises measuring the level of at least one antibody in a test sample obtained from the mammal, which at least one antibody is specific for an antigen that is known to be associated with the pathologic state, and wherein the level of the at least one antibody is indicative of the effectiveness of treatment of the pathologic state in the mammal.

REFERENCES:
patent: 5843648 (1998-12-01), Robbins et al.
patent: 6045788 (2000-04-01), Smith
patent: 6106823 (2000-08-01), Vieira et al.
patent: WO 99/32138 (1999-07-01), None
Callard and Gearing (1994), The Cytokine Factsbook (pp. 97-98).
Beers & Berkow, The Merck Manual, 17th edition, pp. 986-995, (1999).
Aguirre et al., “Role of tumor necrosis factor and gamma interferon in acquired resistance to Cryptococcus neoformans in the central nervous system of mice,”Infect. Immun.,63, 1725-1731 (1995).
Armitage et al.,Nature,357, 80-82 (1992).
Armitage et al., “CD40L: a multi-functional ligand,”Semin. Immunol.,5, 401-412 (1993).
Bag, “Fungal pneumonias in transplant recipients,”Curr. Opin. Pulm. Med.,9, 193-198 (2003).
Banchereau et al., “The CD40 antigen and its ligand,”Annu. Rev. Immunol.,12, 881-922 (1994).
Barchiesi et al., “Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection,”Antimicrob. Agents Chemother.,48, 3312-3316 (2004).
Beers & Berkow,The Merck Manual, 17th Edition,165-177, 986-995 (1999).
Billiau et al., “Immunomodulatory properties of interferon-gamma. An update,”Ann. N.Y. Acad. Sci.,856, 22-32 (1998).
Bogdan, “The function of type I Interferons in antimicrobial immunity,”Curr. Opin. Immunol.,12, 419-424 (2000).
Caux et al., “Activation of human dendritic cells through CD40 cross-linking,”J. Exp. Med.,180, 1263-1272 (1994).
Charlier et al., “Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier,”Am. J. Pathol.,166, 421-432 (2005).
Chen et al., “The gamma interferon receptor is required for the protective pulmonary inflammatory response to Cryptococcus neoformans,”Infect. Immun.,73, 1788-1796 (2005).
Chiller et al., “Effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on polymorphonuclear neutrophils, monocytes or monocytes-derived macrophages combined with voriconazole against Cryptococcus neoformans,”Med. Mycol.,40, 21-26 (2002).
Chuntharapai et al.,Method on Enzymology,288, 15-27 (1997).
Dromer et al., “Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody,”Infect. Immun.,55, 749-752 (1987).
Dullforce et al., “Enhancement of T cell-independent immune responses in vivo by CD40 antibodies,”Nat. Med.,4, 88-91 (1998).
French et al.,Nature Medicine,5(5), 548-553 (1999).
Francisco et al.,Cancer Research 60,3225-3231 (2000).
Funakoshi et al.,Blood, 83(10), 2787-2794 (1994).
Grewal et al., “CD40 and CD154 in cell-mediated immunity,”Annu. Rev. Immunol.,16, 111-135 (1998).
Herring et al., “Induction of Interleukin-12 and gamma Interferon requires tumor necrosis factor alpha for protective T1-cell-mediated immunity to pulmonary Cryptococcus neoformans infection,”Infect. Immun.,70, 2959-2964 (2002).
Huffnagle, “Role of cytokines in T cell immunity to a pulmonary Cryptococcus neoformans infection,”Biol. Signals,5, 215-222 (1996).
Huffnagle et al., “Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans,”J. Immunol.,157, 4529-4536 (1996).
Kawakami et al., “NK cells eliminate Cryptococcus neoformans by potentiating the fungicidal activity of macrophages rather than by directly killing them upon stimulation with IL-12 and IL-18,”Microbiol. Immunol.,44, 1043-1050 (2000).
Koguchi et al., “Cryptococcal infection and Th1-Th2 cytokine balance,”Int. Rev. Immunol.,21, 423-438 (2002).
Kozel et al., Bivalency is required for anticapsular monoclonal antibodies to optimally suppress activation of the alternative complement pathway by the Cryptococcus neoformans capsule,Infect. Immun.,66, 1547-1553 (1998).
Kozel et al., “mAbs to Bacilius anthracis capsular antigen for immunoprotection in antrax and detection of antigenemia,”Proc. Natl. Acad. Sci. U.S.A, 101, 5042-5047 (2004).
Kumaratilake et al., “The role of T lymphocytes in Immunity to Plasmodium falciparum. Enhancement of neutrophil-mediated parasite killing by lymphotoxin and IFN-gamma: comparisions with tumor necrosis factor effects,”J Immunol.,146, 762-767 (1991).
Le Page et al., “Interferon activation and innate immunity,”Rev. Immunogenet.,2, 374-386 (2000).
Leinonen et al., “Class-specific antibody response to group B Neisseria meningitidis capsular polysaccharide: use of polylysine precoating in an enzyme-linked immunosorbent assay,”Infect. Immun.,38, 1203-1207 (1982).
Levy et al., “Clinical spectrum of X-linked hyper-IgM syndrome,”J. Pediatr.,131, 47-54 (1997).
Lutz et al., “Enhancement of antifungal chemotherapy by Interferon-gamma in experimental systemic cryptococcosis,”J. Antimicrob. Chemother.,46, 437-442 (2000).
Ma et al., “CD8 T cell-mediated killing of Cryptococcus neoformans requires granulysin and is dependent on CD4 T cells and IL-15,”J. Immunol.,169, 5787-5795 (2002).
Mambula et al., “Human neutrophil-mediated nonoxidative antifungal activity against Cryptococcus neoformans,”Infect. Immun.,68, 6257-6264 (2004).
Mendiratta et al.,Human Gene Therapy,11, 1851-1862 (Sep. 1, 2000).
Mukherjee et al., “Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin,”B. Antimicrob. Agents Chemother.,38, 580-587 (1994).
Murphy et al., “Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses,”J. Immunol.,170, 2727-2733 (2003).
Pietrella et al., “Disruption of CD40/CD40L interaction influences the course of Cryptococcus neoformans infection,”FEMS Immunol. Med. Microbiol.,40, 63-70 (2004).
Ross et al., “Cryptococcal meningitis and sarcoidosis,”Scand. J. Infect. Dis.,34, 937-939 (2002).
Sabeti et al., “CD40L association with protection from severe malaria,”Genes Immun.,3, 286-291 (2002).
Shoham et al., “The immune response to fungal infections,”Br. J. Haematol.,129, 569-582 (2005).
Siddiqui et al., “IFN-gamma at the site of infection determines rate of clearance of infection In cryptococcal meningitis,”J. Immunol.,174, 1746-1750 (2005).
Sundstrom et al., “The glucuronoxylomannan of Cryptococcus neoformans serotype A is a type 2 T-cell-independent antigen,”Infect. Immun.,60, 4080-4087 (1992).
Uicker et al., “Cytokine and chemokine expression in the central nervous system associated with protective cell-mediated immunity against Cryptococcus neoformans,”Med. Mycol.,43, 27-38 (2005).
Van Kooten et al., “Functions of CD40 on B cells, dendritic cell

Affiliated with

Also associated with

Rating

Use of a promoter of T-cell expansion and an inducer of CD40... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of a promoter of T-cell expansion and an inducer of CD40..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of a promoter of T-cell expansion and an inducer of CD40... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2791744